Suggestions
Rebecca Frey
Chief Operating Officer at EvolveImmune Therapeutics
Professional Background
Rebecca Frey is a versatile C-level executive in the biopharmaceutical sector with a remarkable 20 years of experience across various facets of drug development and company building. Her extensive career has been defined by her roles in senior management and her impactful contributions to the companies she has worked with. As the Chief Operating Officer at EvolveImmune Therapeutics, she has demonstrated her expertise in steering the company towards innovative therapeutic solutions that address significant medical needs.
Prior to her current role, Rebecca served as a Venture Partner at Elm Street Ventures, where she provided strategic insights and guidance to emerging companies in the biopharmaceutical landscape. Her leadership skills were further exemplified during her time on the board of directors for notable organizations like Stealth NewCo and Halda Therapeutics, where she played a pivotal role in shaping high-level strategies that promote growth and operational excellence.
Rebecca's previous appointments also include noteworthy leadership positions such as Chief Operating Officer at Cardurion Pharmaceuticals and Executive Vice President of Operations at Prevail Therapeutics. In these roles, she was instrumental in overseeing large-scale operations and development projects that contributed to the advancement of novel treatments in the biopharmaceutical field. Her career at Alexion Pharmaceuticals, Inc. was particularly significant, wherein she held multiple executive titles including Vice President of Operations and Enterprise Management, Executive Director of Corporate Planning and Development, and Executive Director of Global Drug Development and Project Management. Through these various positions, she has cultivated a deep understanding of the complexities of global drug development, and project management, and has become a sought-after expert in operational efficiency and strategic development.
Education and Achievements
Rebecca Frey's academic credentials are as impressive as her professional accomplishments. She earned her Doctor of Pharmacy (PharmD) at Northeastern University, where she built a strong foundation in pharmaceutical sciences. Following her pharmacy degree, Rebecca continued her education at Northeastern University, completing a Post-Doctoral Fellowship in Transplant Clinical Development. This advanced training has equipped her with specialized knowledge that is crucial for her roles in drug development and clinical research, especially in the fields related to transplantation and immune therapies.
Rebecca's blend of practical experience and educational credentials has positioned her as a thought leader in the biopharmaceutical sector, where she continues to influence advancements in drug development.
Achievements
Throughout her career, Rebecca has achieved numerous milestones that illustrate her dedication and expertise in the biopharmaceutical industry. She has been recognized for building high-performance teams and establishing best practices that have had lasting impacts on the organizations she has worked with.
Her tenure at Alexion Pharmaceuticals, where she transitioned from roles in scientific communications to top executive positions, showcases her range and adaptability. By leading significant projects in global drug development and corporate planning, she has contributed to successful product launches that meet the needs of patients around the world. Moreover, her involvement in the boards of emerging biotech organizations reflects her commitment to fostering innovation and supporting the next generation of therapeutic solutions.
Conclusion
In summary, Rebecca Frey has built an illustrious career as a C-level biopharmaceutical leader and board member, boasting two decades of comprehensive experience in drug development and company building. Her educational background, with a Doctor of Pharmacy from Northeastern University and a Post-Doctoral Fellowship, complements her extensive professional record. As she continues to lead and innovate within the biopharmaceutical field, Rebecca exemplifies the qualities of a dedicated and influential leader, making significant contributions to the industry and the well-being of patients globally.
